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Human CD8 cytotoxic T lymphocytes can mediate tumor
regression in melanoma through the specific recognition of
HLA-restricted peptides. Because of the relatively weak affinity
of most anti-cancer T-cell receptors (TCRs), there is growing
emphasis on immunizing melanoma patients with altered pep-
tide ligands in order to induce strong anti-tumor immunity
capable of breaking tolerance toward these self-antigens. How-
ever, previous studies have shown that these immunogenic
designer peptides are not always effective. The melanocyte dif-
ferentiation protein, glycoprotein 100 (gp100), encodes a natu-
rally processed epitope that is an attractive target formelanoma
immunotherapies, in particular peptide-based vaccines. Previ-
ous studies have shown that substitutions at peptide residue
Glu3 have a broad negative impact on polyclonal T-cell
responses. Here, we describe the first atomic structure of a nat-
ural cognate TCR in complex with this gp100 epitope and
highlight the relatively high affinity of the interaction. Ala-
nine scan mutagenesis performed across the gp100280–288
peptide showed that Glu3 was critically important for TCR
binding. Unexpectedly, structural analysis demonstrated that
the Glu3 3 Ala substitution resulted in a molecular switch
that was transmitted to adjacent residues, abrogating TCR
binding and T-cell recognition. These findings help to clarify
the mechanism of T-cell recognition of gp100 during mela-
noma responses and could direct the development of altered
peptides for vaccination.
Cytotoxic T-cells can mediate a specific response against
autologous melanoma cells by recognizing tumor-derived pep-
tides presented at the cell surface by human leukocyte antigen
(pHLA).6 In particular, epitopes encoded by differentiation
melanocyte proteins may represent shared melanoma-associ-
ated antigens targeted by T-cell receptors (TCRs) on patients’
lymphocytes (1). Glycoprotein 100 (gp100) has been a widely
studied target for melanoma immunotherapy. This 661-amino
acid long melanoma differentiation antigen is a melanosome
matrix protein involved in melanosome maturation and mela-
nin synthesis (2). In vivo, the protein has significantly differen-
tial expression between tumor cells, being often overexpressed
in all stages of melanoma progression, compared with normal
melanocytes (3).
Previous studies showed that gp100 encoded epitopes are
recognized by tumor-infiltrating lymphocytes and circulating
T-cells, associated with tumor regression in metastatic mela-
noma patients after adoptive therapy (4–7). Among these, the
nonamer epitope gp100280–288 (YLEPGPVTA) was originally
shown to be recognized by HLA-A*0201 tumor-infiltrating
lymphocytes from melanoma patients (8) and subsequently
eluted from HLA-A*0201 molecules on melanoma cells (9).
Immunization with gp100280–288 peptide has been shown to
stimulate an in vitro polyclonal T-cell response in the context of
HLA-A*0201, present in 49% of Caucasian individuals (10).
These findings generated renewed interest in developing
gp100-based anti-melanoma vaccines. However, we and others
have previously shown, through direct biophysical measure-
ments, that anti-cancer TCRs bind to their cognate pHLA with
affinities that are approximately 1 order of magnitude weaker
than those of pathogen-specific TCRs (11, 12). Thus, altered
peptide ligands, with improved primary HLA anchor residues
(heteroclitic peptides), have beendesigned for a fewmelanoma-
associated antigens in order to increase immunogenicity (6, 10,
13). Among these, the heteroclitic version of gp100280–288 (in
which a valine replaces alanine at anchor position 9 to improve
pHLA stability (14)) enhanced the induction of melanoma-re-
active cytotoxic T lymphocytes in vitro and has been success-
fully used in clinical trials (15). Another heteroclitic form of
gp100280–288, in which peptide residue Glu3 was substituted to
Ala, abrogated recognition by a polyclonal population of
gp100280–288-specific T-cells (16, 17). Thus, a more complete
understanding of the molecular mechanisms underlying
gp100280–288 targeting by specific TCRs is needed to direct the
design of improved altered peptide ligands.
Previous studies using another HLA-A*0201-restricted mel-
anoma-derived epitope have demonstrated that even minor
changes in peptide anchor residues can substantially alter
T-cell recognition in unpredictableways (13, 18). In order to aid
in the future design of enhanced peptide vaccines based on
gp100280–288, we solved the ternary atomic structure of a
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humanTCR in complexwith the heteroclitic gp100280–288 pep-
tide.We thenused a peptide scanning approach to demonstrate
the impact of peptide substitutions on TCRs from two different
T-cell clones by performing in depth biophysical and functional
experiments. These data demonstrate thatmodification of pep-
tide residues outside of the TCR bindingmotif can have unpre-
dictable knock-on effects (a modification to a residue that
affects an adjacent residue indirectly) on adjacent peptide resi-
dues that abrogate TCRbinding andT-cell recognition. Indeed,
even conservative peptide substitutions can have unexpected
consequences for T-cell recognition due to knock-on structural
changes in the HLA-bound peptide. Our findings provide a
molecular explanation for the sensitivity to substitutions at
gp100280–288 peptide residue Glu3 (16, 17) and represent the
first example of the structural mechanisms underlying T-cell
recognition of this important therapeutic target for melanoma.
Experimental Procedures
Generation of Expression Plasmids—The PMEL17 TCR
(TRAV21 TRBV7-3) (12) and gp100 TCR (TRAV17 TRBV19)
(11) are both specific for the human HLA-A*0201 restricted
YLE epitope (gp100280–288, sequence YLEPGPVTA). For each
TCR, a disulfide-linked construct was used to produce the sol-
uble - and -chain domains (variable and constant) (19, 20).
The HLA*0201 -chain and 2m sequences were generated by
PCR cloning. All sequences were confirmed by automated
DNA sequencing (Cardiff Biotechnology Service). For surface
plasmon resonance (SPR) experiments, the soluble HLA-
A*0201 -chain was tagged with a biotinylation sequence, as
described previously (21). All four constructs (TCR, TCR,
HLA-A*0201 -chain, and 2m) were inserted into separate
pGMT7 expression plasmids under the control of the T7 pro-
moter (20).
Protein Expression, Refolding, and Purification—Competent
Rosetta DE3 Escherichia coli cells were used to produce the
PMEL17 TCR, gp100 TCR  and  chains, and HLA-A*0201 
and 2m chains in the form of inclusion bodies, using 0.5 M
isopropyl 1-thio--D-galactopyranoside to induce expression.
Soluble PMEL17 TCR, gp100 TCR, and pHLA proteins were
refolded as described previously (19, 20), purified by anion
exchange (Poros 50HQ, Life Technologies, Cheshire, UK) and
size exclusion chromatography (S200 GR, GE Healthcare,
Buckinghamshire, UK). For the pHLAs, HLA-A*0201 was
refoldedwith YLEPGPVTA (A2-YLE), YLEPGPVTV (A2-YLE-
9V),ALEPGPVTA (A2-YLE-1A), YLAPGPVTA (A2-YLE-3A),
YLEAGPVTA (A2-YLE-4A), YLEPAPVTA (A2-YLE-5A),
YLEPGAVTA (A2-YLE-6A), YLEPGPATA (A2-YLE-7A), or
YLEPGPVAA (A2-YLE-8A).
SPR Analysis—The binding analysis was performed using a
BIAcore 3000 or Biacore T100 equipped with a CM5 sensor
chip as reported previously (21). Briefly, 500–600 response
units of biotinylated pHLA-I complexes were immobilized to
streptavidin, which was chemically linked by amine coupling to
the chip surface. Biotinylated pHLA-I complexes were pre-
pared as described previously (21) and injected at a slow flow
rate (10 l/min) to ensure a uniform distribution on the chip
surface. Results were analyzed using BIAevaluationTM version
3.1, Microsoft ExcelTM, and OriginTM version 6.0. For equilib-
rium analysis, 9–10 serial dilutions of concentrated TCR were
injected over the relevant sensor chip. The equilibrium-binding
constant (KD(E)) values were calculated using a nonlinear curve
fit (y (P1x)/(P2 x)). For the thermodynamics experiments,
KD values determined by SPR at different temperatures
were used with the standard thermodynamic equation
G0RTlnKD. The thermodynamic parameters were calcu-
lated according to the Gibbs-Helmholtz equation (G0H -
TS0). The binding free energies,G0 (G0RTlnKD), were
plotted against temperature (K) using nonlinear regression
to fit the three-parameter equation, (y  H  Cp*(x 
298)  x*S  x*Cp*ln(x/298)). For kinetics analysis, the
Kon and Koff values were calculated assuming 1:1 Langmuir
binding, and the data were analyzed using a global fit algo-
rithm (BIAevaluationTM version 3.1). All SPR experiments
were conducted in triplicate.
Crystallization, Diffraction Data Collection, and Model
Refinement—All protein crystals were grown at 18 °C by vapor
diffusion via the sitting drop technique. 200 nl of 1:1molar ratio
TCR and pHLA-I (10 mg/ml) in crystallization buffer (10 mM
Tris, pH 8.1, and 10 mMNaCl) was added to 200 nl of reservoir
solution. PMEL17 TCRA2-YLE-9V crystals were grown in 0.2
M sodium sulfate, 0.1 M Bistris propane, pH 6.5, 20% (w/v) PEG
3350. Crystals of pHLAcomplexeswere grown at 18 °C by seed-
ing into hanging drops of 0.5 l of seeding solution  1 l of
complex  1 l of 0.1 M Hepes, pH 7.5, 0.2 M ammonium sul-
fate, 25% PEG 4000 (22). Data were collected at 100 K at the
Diamond Light Source (Oxfordshire, UK). All data sets were
collected at a wavelength of 0.976 Å using an ADSCQ315 CCD
detector. Reflection intensities were estimated with the XIA2
package (23), and the data were scaled, reduced, and analyzed
with SCALA and the CCP4 package (24). Structures were
solved by molecular replacement using PHASER (25).
Sequences were adjusted with COOT (26) and the models
refined with REFMAC5 (27). Graphical representations were
preparedwith PyMOL (28). Data reduction and refinement sta-
tistics are shown in Table 1. The reflection data and final model
coordinates were deposited in the Protein Data Bank (entries
5EU6 (PMEL17 TCRA2-YLE-9V), 5EU3 (A2-YLE), 5EU4 (A2-
YLE-3A), and 5EU5 (A2-YLE-5A)).
Isothermal Titration Calorimetry (ITC)—ITC experiments
were performed using a Microcal VP-ITC (GE Healthcare) as
described previously (29), with 30 M pHLA-I in the calorime-
ter cell and 210 M soluble PMEL17 TCR in the syringe. Buffer
conditions were 20 mM Hepes (pH 7.4) containing 150 mM
NaCl, and 20 injections of 2 l each were performed. Results
were processed and integrated with the OriginTM version 6.0
software distributed with the instrument. ITC experiments
were performed in duplicate.
Lentivirus Generation and Transduction of CD8 T-cells—
Lentivirus particles were generated by combining packaging
plasmids pRSV, pMDL, and pVSG-V with a lentivirus plasmid
bearing the gp100 TCR construct (provided by Immunocore
Ltd., Oxford, UK) and used to CaCl2-transfect HEK293T/17
(ATCC) cells. Supernatant was collected after 24- and 48-h
incubations, and lentiviral stocks were concentrated by ultra-
centrifugation. Primary CD8 T-cells were obtained by stan-
dard density gradient centrifugation from donor blood bags,
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followed by positive selection using CD8 microbeads (Miltenyi
Biotec). Cells were activated overnight with anti-CD3/CD28
Dynabeads (Invitrogen) (1:1) and transduced with concen-
trated lentivirus particles. Transduction efficiency was deter-
mined after 72 h by flow cytometry after staining with the rel-
evant anti-TCRVmAb (BD Biosciences). Untransduced cells
or MEL5 TCR (specific for the Melan-A/MART-1 epitope
ELAGIGILTV)-transduced cells were used as controls (data
not shown). Transductions were performed using primary
CD8 T-cells from three different anonymous donors.
Measurement of MIP-1 and TNF by ELISA—To quantify
the production of MIP-1 and TNF, 6  104 T2 target cells
were pulsed with peptide as indicated for 1 h and added to
3  104 overnight rested T-cells. Following overnight incuba-
tion, cells were pelleted, and the culture supernatant was har-
vested for measurement of MIP-1 and TNF by ELISA
according to themanufacturer’s protocol (R&D Systems). Each
data point represents the average of duplicate measurements.
Cytotoxicity Assay—Cytotoxic assays in this study were per-
formed in a standard 4-h 51Cr release assay. Briefly, 2 103 T2
cells were labeled with 51Cr (PerkinElmer Life Sciences) and
then pulsed with peptide at the indicated concentration and
used as target cells. Effector and target cells, at an effector/
target ratio of 5, were incubated for 4 h at 37 °C, and the super-
natant was harvested. Target cells were also incubated alone or
with 5% Triton X-100 detergent to give the spontaneous and
total 51Cr released from the target cells, respectively. 51Cr
release was determined by -counting (1450 Microbeta coun-
ter, PerkinElmer Life Sciences). The percentage of specific cell
lysis was calculated according to the following formula: (exper-
imental release (with effector and target cells)  spontaneous
release from target cells)/(total release from target cells spon-
taneous release from target cells) 100. Each data point repre-
sents the average of duplicate measurements.
Results
Two Distinct Anti-gp100 TCRs Share Similar Binding Hot
Spots—The CD8T-cell responses directed against gp100280–288
have been shown to be polyclonal in nature (16, 17). Along with
the two TCRs under investigation here, the sequences of a fur-
ther two TCRs have been published, demonstrating diverse
gene usage and different CDR3 loop sequences (Table 1).
Despite these differences, previous studies of T-cell responses
to gp100280–288 have demonstrated that modifications to pep-
tide residue Glu3 can broadly effect activation of gp100280–288-
specific T-cells (16, 17). Thus, in order to study the individual
contribution of the peptide residues involved in TCR recogni-
tion of gp100280–288, particularly in relation to peptide residues
Glu3, an alanine scan mutagenesis was performed across the
peptide backbone, and TCR binding affinity was evaluated by
SPR experiments. Residues P2 and P9, which are known to be
important for HLA-A*0201 binding (30) were not assessed; in
addition, the P9 residue was an Ala in the native sequence. The
heteroclitic YLE-9V peptide, which has been shown to be a
better agonist than the wild type sequence (10), was included in
the experiment. SPR experimentswere conductedwith twodis-
tinct gp100280–288-specific TCRs: PMEL17 TCR (TRAV21
TRBV7-3) and gp100 TCR (TRAV17 TRBV19). PMEL17 TCR
bound both A2-YLE and A2-YLE-9V with similar affinities
(KD 7.6 and 6.3M, respectively), consistentwith the fact that
the YLE-9V variant was originally designed in such a way as to
increase peptide-HLA binding affinity without significantly
altering TCR recognition of the pHLA complex (10) (Table 2).
The gp100 TCR demonstrated a similar pattern, although at
weaker affinities, of KD  26.5 and 21.9 M, for A2-YLE and
A2-YLE-9V, respectively. With the exception of A2-YLE-3A
and A2-YLE-5A, both the PMEL17 and gp100 TCRs tolerated
substitutions in the native gp100280–288 peptide, albeit with
reduced binding affinity, although substitutions at the peptide
C terminus generally reduced binding affinity to a greater
extent than at the N terminus. Substitution of peptide residue 5
to alanine reduced the affinity for both TCRs to KD 1 mM.
Interestingly, replacement of Glu by Ala in position 3 com-
pletely abrogated binding by PMEL17 and gp100 TCRs, sug-
gesting that the Glu at p3 was a dominant contact for both
TCRs.Our results are supported by a recent study of gp100280–288
altered peptide ligands, which described YLE-3A as a null ago-
nist for a different TCR (17). Our data indicated that both
PMEL17 and gp100 TCRs used a similar overall binding mode,
focused around peptide residues 3 and 5 with supporting inter-
actions toward the N terminus of the peptide. In combination
with other data in this system (17), alanine substitution data
suggest that disparate TCRs adopt a similar binding mode on
A2-YLE, where position 3 dominates recognition. In order to
confirm this hypothesis, we crystallized the PMEL17 TCR in
complex with A2-YLE-9V.
The PMEL17 TCRUtilizes a Peptide-centric BindingMode to
Engage A2-YLE-9V—To understand why TCR recognition of
gp100280–288 was highly sensitive to some of the substitutions
in the native peptide sequence, we determined the crystal struc-
TABLE 1
Alignment of TCR CDR3 regions of PMEL17, gp100, MPD (16), and 296 gp100-specific TCRs (16)
TCR CDR1 CDR2 CDR3 CDR1 CDR1 CDR1
PMEL17 DSAIYN IQSSQRE CAVLSSGGSNYKLTFG SGHTA FQGTGA CASSFIGGTDTQYFG
gp100 TSINN IRSNERE CATDGDTPLVFG LNHDA SQIVND CASSIGGPYEQYFG
MPD KALYS LLKGGEQ CGTETNTGNQFYFG SGHDY FNNNVP CASSLGRYNEQFFG
296 DSASNY IRSNVGE CAASTSGGTSYGKLTFG MNHEY SMNVEV CASSLGSSYEQYFG
TABLE 2
Affinity analysis (KD) of PMEL17 TCR and gp100 TCR to gp100
280–288
peptide variants
Peptide
sequence Peptide
PMEL17 TCR (TRAV21
TRBV7-3), affinity KD
gp100 TCR (TRAV17
TRBV19), affinity KD
YLEPGPVTA YLE 7.6 2 M 26.5 2.3 M
YLEPGPVTV YLE-9V 6.3 1.2 M 21.9 2.4 M
ALEPGPVTA YLE-1A 15.9 4.1 M 60.6 5.4 M
YLAPGPVTA YLE-3A No binding No binding
YLEAGPVTA YLE-4A 19.7 1.3 M 144.1 7.8 M
YLEPAPVTA YLE-5A 1 mM 1 mM
YLEPGAVTA YLE-6A 11.4 2.7 M 954.9 97.8 M
YLEPGPATA YLE-7A 31.1 4 M 102.0 9.2 M
YLEPGPVAA YLE-8A 38.1 7.4 M 121.0 7.5 M
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ture of the PMEL17 TCR in complex with A2-YLE-9V at 2.02 Å
resolution with crystallographic Rwork/Rfree ratios within
accepted limits (Table 3) as shown in the theoretically expected
distribution (31). Electron density around the TCRpHLA con-
tact interface was unambiguous (Fig. 1). The PMEL17 TCRwas
centrally positioned over the exposed residues of the peptide
(Fig. 2, A and B) and used a conventional diagonal orientation
(crossing angle  46.15°, calculated as in Ref. 32), with the
-chain positioned over the 2 helix of the HLA-I binding
groove and the -chain over the 1 helix. All but the CDR2
loop were involved in contacting A2-YLE-9V, with the CDR3
and CDR3 “sitting” on the central axis of the antigen-binding
cleft, making contacts with both the peptide and -helices of
the HLA (Fig. 1B). The PMEL17 TCR made approximately the
same number of peptide-mediated contacts and HLA-A*0201
interactions, forming 53 of 125 (42.4%) van derWaals contacts
and 3 of 8 (37.5%) hydrogen bonds between the TCR and the
peptide (Table 4). The HLA helices were contacted by residues
within the CDR3, CDR3, and CDR2 loops (with additional
support of CDR1 residue Tyr32), which focused on Arg65,
Ala69, Gln72, andGln155 (Fig. 1C). HLA residues at positions 65,
69, and 155 are conserved TCR-mediated contact points in sev-
eral TCRpHLA-I structures determined so far and are referred
to as the “restriction triad” (33).
To complement information gained from the crystal struc-
ture, we studied the affinity and thermodynamic parameters of
the PMEL17 TCRA2-YLE complex. The binding strength of
the complex was measured at 5, 12, 18, 25, and 37 °C by SPR
(Fig. 3A). The PMEL17 TCRA2-YLE interaction at 25 °C (the
standard temperature for TCRpHLA parameter measure-
ments) was characterized by a binding G of 7.5 kcal/mol,
FIGURE 1.Density plot analysis. The left column shows omitmaps inwhich the
modelwas refined in theabsenceof thepeptide.Differencedensity is contoured
at 3.0; positive contours are shown ingreen, andnegative contours are red. The
right-handcolumn shows theobservedmapat1.0 (shownasgraymesharound
stick representations of the protein chains) after subsequent refinement using
automatic non-crystallographic symmetry restraints applied by REFMAC5. A,
model forPMEL17TCRA2-YLE-9Vwith theTCRCDR3 loops coloredblue (chain)
and orange ( chain) and the peptide in green; B, model for A2-YLE with the
peptide colored dark green; C, model for A2-YLE-3A with the peptide colored
orange (for A2-YLE-3A, there were two molecules in the asymmetric unit, but
thesewere virtually identical in termsof omit anddensitymaps, soonly copy1 is
shown here);D, model for A2-YLE-5Awith the peptide colored pink.
TABLE 3
Data reduction and refinement statistics (molecular replacement)
Parameters PMEL17 TCRA2-YLE-9V A2-YLE A2-YLE-3A A2-YLE-5A
Protein Data Bank code 5EU6 5EU3 5EU4 5EU5
Data set statistics
Space group P1 P1 21 1 P1 P1 21 1
Unit cell parameters (Å) a 45.52, b 54.41, c 112.12,
 85.0°,  81.6°,  72.6°
a 52.81, b 80.37,
c 56.06,  112.8°
a 56.08, b 57.63, c 79.93,
 90.0°,  89.8°,  63.8°
a 56.33, b 79.64,
c 57.74,  116.2°
Radiation source DIAMOND I03 DIAMOND I03 DIAMOND I02 DIAMOND I02
Wavelength (Å) 0.9763 0.9999 0.9763 0.9763
Measured resolution range (Å) 51.87–2.02 45.25–1.97 43.39–2.12 43.42–1.54
Outer Resolution Shell (Å) 2.07–2.02 2.02–1.97 2.18–2.12 1.58–154
Reflections observed 128,191 (8,955) 99,442 (7,056) 99,386 (7,463) 244,577 (17,745)
Unique reflections 64,983 (4,785) 30,103 (2,249) 49,667 (3,636) 67,308 (4,962)
Completeness (%) 97.7 (96.7) 98.5 (99.3) 97.4 (96.7) 99.6 (99.9)
Multiplicity 2.0 (1.9) 3.3 (3.1) 2.0 (2.1) 3.6 (3.6)
I/(I) 5.5 (1.9) 7.2 (1.9) 6.7 (2.3) 13 (2.3)
Rpim (%) 5.7 (39.8) 8.8 (44.7) 8.7 (41.6) 4.5 (35.4)
Rmerge (%) 7.8 (39.6) 9.8 (50.2) 8.7 (41.6) 5.0 (53.2)
Refinement statistics
Resolution (Å) 2.02 1.97 2.12 1.54
No. of reflections used 61,688 28,557 47,153 63,875
No. of reflections in Rfree set 3294 1526 2514 3406
Rcryst (no cut-off) (%) 18.1 19.7 17.2 17.0
Rfree 22.2 25.5 21.1 20.1
Root mean square deviation from
ideal geometry
Bond lengths (Å) 0.018 (0.019)a 0.019 (0.019) 0.021 (0.019) 0.018 (0.019)
Bond angles (degrees) 1.964 (1.939) 1.961 (1.926) 2.067 (1.927) 1.914 (1.936)
Overall coordinate error (Å) 0.122 0.153 0.147 .055
Ramachandran statistics
Most favored 791 (96%) 371 (98%) 749 (99%) 384 (98%)
Allowed 32 (4%) 6 (2%) 10 (1%) 5 (1%)
Outliers 2 (0%) 3 (1%) 1 (0%) 2 (0%)
a Values in parentheses are for the highest resolution shell.
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which is within the normal range of TCRpHLA interactions
(34). PMEL17 TCRA2-YLE binding was characterized by a
very small, favorable enthalpy change (H  0.6 kcal/mol)
and a larger, positive entropy change (TS 6.9 cal/mol) (Fig.
3B). Therefore, order to disorder drove the interaction, proba-
bly through the expulsion of ordered water molecules at the
interface (i.e. solvation effects). ITC was also performed
because it provides a direct measure of enthalpy and is there-
fore considered the most reliable determination of thermody-
namic parameters (29). ITC measurements (H  0.3 kcal/
mol andTS 5.6 cal/mol) confirmed observationsmadewith
SPR thermodynamics (Fig. 3C). The favorable enthalpy of this
TCRpHLA system shows that the overall number of formed
bonds is equal to the number of disrupted ones upon PMEL17
TCR binding.
The PMEL17 CDR Loops Focus on Peptide Residues Pro4,
Val7, and Thr8—The central positioning of the PMEL17 TCR
enabled contacts with 6 of 9 amino acids in the peptide (Fig.
4A). Peptide residues Pro4, Val7, and Thr8 represented the focal
points of the PMEL17 TCR. Pro4 made a sizeable network of
interactions (1 hydrogen bond and 14 van der Waal contacts)
(Fig. 4B). Interestingly, Pro6 was the only central residue that
did not interact with the PMEL17 TCR because of its reduced
surface exposure. Therefore, the relative insensitivity of the
PMEL17 TCR to alanine substitution at position 6 is consistent
with its lack of involvement in TCR binding. In contrast, the
gp100 TCR seemed to be more sensitive to this samemutation,
causing a	40-fold drop in binding affinity compared with the
unaltered peptide (Table 2). This might be explained by the
differentTRAV andTRBV gene usage of the two gp100-specific
TCRs and the very different residues of the CDR3 loops possi-
bly contacting the central part of the gp100280–288 peptide.
However, the PMEL17 TCR complex structure did not provide
any clear mechanisms to explain the reduction in binding
observed when peptide residues 3 and 5 were mutated to
alanine.
Peptide Substitutions Can Induce Perturbation at Adjacent
Peptide Residues Abrogating T-cell Recognition—In order to
understand the structural basis underlying the large changes in
affinity of PMEL17 TCRA2-YLE binding resulting from
Glu33 Ala and Gly53 Ala substitutions, we also solved the
unligated structures of A2-YLE, A2-YLE-3A, and A2-YLE-5A.
The structures were solved between 1.54 and 2.12 Å resolution
with crystallographic Rwork/Rfree ratios within accepted limits
(Table 3) (31). Electron density around the peptide was unam-
biguous (Fig. 1). Comparison of the crystallographic structure
of A2-YLE and A2-YLE-3A or A2-YLE-5A complexes did not
reveal major changes in the peptide backbone conformation
(Fig. 5, A and B). However, in the A2-YLE structure, Glu3
bridges across to the main chain at position 4–5; the mutation
of Glu3 into a shorter alanine side chain, which is no longer able
FIGURE 2. Overview of the PMEL17 TCR in complex with A2-YLE-9V. A,
schematic representation of the PMEL17 TCRA2-YLE-9V complex. The TCR
-chain and TCR-chain are dark gray and black, respectively; TCR CDR loops
are shown (red, CDR1; dark green, CDR2; blue, CDR3; yellow, CDR1; aqua,
CDR2; orange, CDR3); the HLA-A*0201 is depicted in gray. The YLE-9V pep-
tide is represented in green sticks. B, surface and stick representation of resi-
dues of the PMEL17 TCR CDR loops (color-coded as in A) that contact the
A2-YLE surface (A2, gray; YLE-9V, green sticks). Black diagonal line, crossing
angle of the TCR with respect to the long axis of the YLEPGPVTV peptide
(46.15°).C, contact footprint of the PMEL17 TCRon theA2-YLE-9V surface (A2,
gray); purple and green (surface and sticks) indicate HLA-A*0201 and YLE res-
idues, respectively, contacted by the gp100 TCR (cut-off of 3.4 Å for hydrogen
bonds and 4 Å for van der Waals contacts).
TABLE 4
PMEL17 TCRA2-YLE-9V contact table
HLA/peptide
residue TCR residue
No. of van der Waals
contacts (<4 Å)
No. of hydrogen
bonds (<3.4 Å)
Gly62 Gly98 3
Ser99 1
Arg65 Ser99 2
Arg65 O Asn100 N2 2 1
Arg65 NH1 Asp58 O2 1
Ser59 8
Lys66 Gly98 1
Ser99 4
Asn100 4
Ala69 Asn100 2
Ala56 2
Gln72 N2 Gln51 O 3 1
Gly54 7
Ala55 1
Thr73 Gln51 1
Val76 Gln51 3
Gly52 2
Lys146 Phe97 3
Ile98 3
Ala150 Ile98 1
Asp102 3
Val152 Ile98 1
Glu154 Tyr32 1
Gln155 N Tyr32 OH 4 1
Gln155 O1 Thr101 N 10 1
Tyr1 OH Gly97 O 1 1
Gly98 1
Ser96 1
Glu3 Tyr101 1
Pro4 Ser96 1
Ser99 1
Asn100 4
Pro4 O Tyr101 N 14 1
Gly5 Tyr101 3
Gly100 2
Val7 Ile98 7
Gly99 2
Gly100 2
Thr8 Thr31 5
Gln51 1
Phe97 1
Thr8 N Ile98 O 6 1
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to bridge across the void, caused a knock-on effect on the cen-
tral Pro4 residue (Fig. 5A). This difference could not be
explained by the difference in resolution and coordinate errors
in the A2-YLE-3A structure (A2-YLE-3A was solved at 2.12 Å,
compared with 1.97 Å for A2-YLE and 1.54 Å for A2-YLE-5A),
demonstrated by omit map analysis shown in Fig. 1. Pro4 in the
A2-YLE-3A structure lost restraint, causing the oxygen atom to
flip in the opposite direction. Because of this unanticipated dis-
placement of the Pro4 oxygen, the outward facing side of the
Pro4 residue was no longer in an optimal position to be con-
tacted by the TCR, therefore potentially losing the dominant
network of interactions (Fig. 4B). These findings explain the
complete absence ofmeasurable binding of the YLE-3Amutant
in the alanine scan. Gly5 was the only gp100280–288 peptide
residue contacted by both CDR3 loops through Tyr101 and
Gly100 in the PMEL17 TCRA2-YLE-9V structure (Fig. 5B). In
the A2-YLE-5A structure, steric hindrance in the center of the
peptide may explain the substantial reduction in binding affin-
ity observed in the alanine scan. As with YLE-3A, the YLE-5A
substitution did not distort the overall conformation of the YLE
nonamer.
Alanine Substitutions at YLE Peptide Residues 3 and 5 Abro-
gate T-cell Activation—To determine the effect of gp100280–288
altered peptide ligands on the activation of T-cells, we exam-
ined the ability of these mutants to induceMIP-1, TNF pro-
duction and specific cytotoxicity (Fig. 6). These are key effector
functions of activated CD8 T-cells, which can be measured
over a wide range of peptide concentrations. Human primary
CD8 T-cells were transduced with a lentiviral construct car-
rying the gp100 TCR and enriched for high and equal levels of
TCR expression. Staining with TCRV mAb showed that
	40% of total CD8 T-cells stained as positive for gp100 TCR
expression by flow cytometry in three independent donors
FIGURE 3. Thermodynamic analysis of the PMEL17 TCRA2-YLE interaction. A, PMEL17 TCR equilibrium-binding responses to A2-YLE at 5, 12, 18, 25, and
37 °C across 9–10 TCR serial dilutions. SPR raw and fitted data (assuming 1:1 Langmuir binding) are shown in the inset of each curve andwere used to calculate
Kon and Koff values using a global fit algorithm (BIAevaluation version 3.1). The table shows equilibrium-binding (KD(E)) and kinetic-binding constant (KD(K)
Koff/Kon) at each temperature. The equilibriumbinding constant (KD,M) valueswere calculated using a nonlinear fit (y (P1x)/(P2 x)). B, the thermodynamic
parameters were calculated according to the Gibbs-Helmholtz equation (G0H TS0). The binding free energies, G0 (G0RTlnKD), were plotted
against temperature (K) usingnonlinear regression to fit the three-parameter equation (ydHdCp*(x298) x*dS x*dCp*ln(x/298)). Enthalpy (H0) and
entropy (TS0) at 298 K (25 °C) are shown in kcal/mol and were calculated by a non-linear regression of temperature (K) plotted against the free energy (G0).
C, ITC measurements for PMEL17 TCRA2-YLE interaction. Enthalpy (H0) and entropy (TS0) at 298 K (25 °C) are shown in kcal/mol.
FIGURE 4. The PMEL17 CDR loops focus on peptide residues Pro4, Val7,
and Thr8. A, schematic representation of contacts between YLE-9V peptide
and PMEL17 CDR loop residues (color-coded as in Fig. 2A). The numbers at the
bottom show total contacts between the TCR and peptide. B, contacts
between the PMEL17 TCR and the YLE-9V peptide (green sticks), showing the
van der Waals contacts (black dashed lines) and hydrogen bonds (red dashed
lines) made by the TCR CDR3 (blue), CDR1 (yellow), CDR2 (aqua), and
CDR3 (orange) loops.Bottompanel, close viewof contactsbetweenYLEPro4,
Val7, and Thr8, respectively, and TCR CDR loop residues (sticks color-coded as
in Fig. 1A) (cut-off of 3.4 Å for hydrogen bonds and a cut-off of 4 Å for van der
Waals contacts).
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(data not shown). Transduced CD8 T-cells were stimulated
with peptide-pulsed HLA-A*0201 T2 target cells, across a
range of different concentrations of gp100280–288 altered pep-
tide ligands. Antigen-specific responses of gp100 TCR-engi-
neered T-cells were validated at the level of production of
MIP-1 and specific lysis of pulsed targets. Non-transduced
CD8 T-cells were used to control for nonspecific activation
through the endogenous TCR; T-cells transduced with the
MEL5 TCR (specific for the HLA-A*0201 restricted cancer
epitope ELA from theMelan-A/MART-1 protein) were used as
an irrelevant control in all experiments (data not shown). Pep-
tide titration experiments showed marked differences in the
ability to sensitize target cells for MIP-1 production by CD8
gp100-specificT-cells (Fig. 6A). In particular, target cells pulsed
with YLE and YLE-9V were recognized more efficiently than
those pulsed with YLE-1A, YLE-8A, YLE-4A, and YLE-7A. No
MIP-1 production was measured with YLE-3A and YLE-5A
peptide ligands, even at higher peptide concentrations. TNF
production was measured by ELISA from the same superna-
tants (Fig. 6C), and low levels of this cytokine were only
detected when cells were pulsed with YLE, YLE-9V, YLE-8A, or
YLE-6A. Fig. 6B shows specific lysis of target cells pulsed with
the same range of peptides and measured by a 51Cr release
assay. Similar to the MIP-1 response curves, the specific lysis
induced by these altered gp100280–288 ligands was variable.
Most importantly, no cytotoxic T lymphocyte-mediated lysis
was observed when peptide YLE-3A or YLE-5A was used.
Taken together, these data are consistent with the molecular
analysis demonstrating that the structural and biophysical
alterations induced by peptide modifications translate directly
to the effects that we observed upon T-cell recognition.
Discussion
TCRs specific for cancer epitopes are generally characterized
by low binding affinities (binding KD values in the high micro-
molar range) (35). This lower binding affinity is thought to be a
result of negative selection of T-cells that bear TCRs with
higher affinity for self-ligands in the thymus. Because TCR
affinity plays an important role in T-cell activation, the TCR
affinity gap between anti-pathogen and anti-cancer T-cells
leaves the latter at a distinct disadvantage and makes it more
difficult to break self-tolerance to such antigens. One approach
to enhance the T-cell response to tumor antigen-derived pep-
tides has been to immunize patients with altered peptide
ligands that differ from the native sequence by a single or mul-
tiple amino acid residues. However, such “heteroclitic” pep-
tides with even single amino acid substitutions that are pre-
dicted to only contact the HLA can have unpredictable, yet
important, effects on TCR engagement. To date, only a few
x-ray structures of TCRs bound to cognate tumor antigens have
been determined (18, 36–38). Given the growing evidence that
plasticity at the TCRpHLA interface can influence immune
recognition (39), structural and biophysical studies should be
taken into account when attempting to design altered peptide
ligands with improved immunogenicity.
We solved the first structure of a naturally occurring TCR
in complex with a gp100 HLA-A*0201-restricted melanoma
epitope. Overall, the PMEL17 TCR bound with a typical diago-
nal orientation over the central peptide residues and mainly
contacted residues 4, 7, and 8 of the YLE peptide, which pro-
truded out of the HLA-A*0201 binding groove. It is important
to underscore that the PMEL17 TCR was characterized by a
binding affinity (KD) of 7.6 M. This value falls at the very high
end of the affinity range described so far for cancer TCRs (11,
35). These results suggest that T-cells bearing TCRs with rea-
sonable affinity for some tumor-associated antigensmay escape
central tolerance, opening the door to further TCR engineering
for medical applications (40).
We also provide insight into the role of each residue in
gp100280–288 duringTCR recognition by performing an alanine
scan mutagenesis with two different gp100280–288-specific
TCRs. With regard to HLA anchor-modified “heteroclitic”
peptides, previous studies have shown that even highly immu-
nogenic designer peptides (e.g. ELA epitope from Melan-A/
MART-1 protein) do not necessarily induce a better clinical
response (13, 41, 42). Fortunately, this is not the case for the
gp100 YLE-9V peptide, which has been successfully adopted in
clinical trials (15). These observations are consistentwith our in
vitro findings, in that the A2-YLE-9V bound with similar affin-
ity to PMEL17 TCR and gp100 TCR compared with the native
peptide. Interestingly, both the PMEL17 TCR (TRAV21
TRBV7-3) and gp100 TCR (TRAV17 TRBV19) were most sen-
sitive to mutations at position 3 or 5 of the native gp100280–288
peptide sequence despite these TCRs being constructed from
completely different V and V genes. A previous study of
gp100 altered peptide ligands also showed the YLE-3A mutant
to be a null agonist when tested on gp100-specific TCR-trans-
FIGURE 5. Conformational comparison of YLE, YLE-3A, and A2-YLE-5A
peptides presented by HLA-A*0201. A, YLE (dark green sticks) and YLE-3A
(orange sticks) peptide alignment by superimposition of HLA-A*02011helix
(gray schematic). Boxed residues indicate themutation of Glu3 into an alanine.
The insets show how the Glu33 Ala substitution causes a shift in position
(black arrow) of neighbor residue Pro4 in the A2-YLE-3A structure compared
with the A2-YLE structure. B, YLE (dark green sticks) and YLE-5A (pink sticks)
peptide alignment by superimposition of HLA-A*0201 1 helix (gray sche-
matic). Boxed residues indicate the mutation of glycine 5 into an alanine.
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fected human T-cells (17). Our results provide a molecular
explanation for this finding.
We show that PMEL17 TCR non-responsiveness to
A2-YLE-3Awas caused by an unexpectedmolecular switch in the
peptide, repositioning the Pro4 residue, whichwas at the center of
a sizeable network of interactions (both van der Waals contacts
and hydrogen bonds) in the PMEL17A2-YLE-9V structure. Posi-
tion3 inHLA-A*0201 restrictedpeptides is known tobe a second-
ary anchor residue (43), in that it supports the exposed peptide
bulge that is normally involved in TCR binding. Interestingly,
mutation in position 3 in theYLEpeptide did not alter the confor-
mation of the peptide backbone itself but resulted in a “knock-on”
effect on the neighboring residue Pro4 that completely abolished
TCRbinding andT-cell recognition.Wehave recently described a
similar molecular switch in an HIV-1-derived peptide, with
important implications for the immune control of HIV infection
and patterns of viral escape mutants (44). Additionally, we have
demonstrated the existence of a novel mode of flexible peptide
presentation in a diabetes model, showing the dynamic nature of
the region surrounding the HLA F-pocket (39, 45). Taken
together, these studies highlight that the peptide-HLA interaction
is more plastic and dynamic than previously appreciated, with
obvious implications for immune recognition, epitope prediction,
and structural modeling.
Overall, our results represent the first structural insight into
TCR recognition of an important tumor antigen, targeted by
many clinical therapies. These data reveal that two very differ-
ent TCRs share a similar pattern of specificity, demonstrated by
their nearly identical sensitivity to different peptide modifica-
tions. Finally, we show that even changes in a single peptide
residue that are not heavily engaged by a TCR can have impor-
tant, knock-on effects on other residues in anHLA-bound pep-
tide that can dramatically alter T-cell recognition. Such “trans-
mitted” structural changes need to be taken into consideration
when designing improved peptides for cancer vaccination.
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